Wuxi Fuxin Pharmaceutical Research and Development

Wuxi Fuxin Pharmaceutical Research and Development is a specialized research and development subsidiary of Fosun Pharma, located in Wuxi, China. The company focuses on the discovery and early-stage development of innovative small molecule therapeutics, particularly in the fields of oncology, metabolic diseases, and rare conditions. It operates as a key component of Fosun Pharma's global R&D network, advancing a pipeline of proprietary compounds designated with the 'FCN' prefix. Notable programs include the MEK inhibitor FCN-159, which has reached Phase 3 clinical trials for neurofibromatosis type 1, and the BCL-2 inhibitor FCN-338 for hematological malignancies. By leveraging advanced medicinal chemistry and pharmacology, Wuxi Fuxin aims to deliver high-quality, innovative treatments to address significant unmet medical needs.